Capital Bank & Trust CO Bluebird Bio, Inc. Transaction History

Capital Bank & Trust CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $7,566 - $12,825	-279 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $18,364 - $44,577	-702 Reduced 71.56%	279 $13,000
Q4 2019 Feb 18, 2020	SELL	$46.96 - $61.67 $6.64 Million - $8.72 Million	-141,372 Reduced 99.31%	981 $86,000
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $3.7 Million - $5.79 Million	62,196 Added 77.59%	142,353 $13.1 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $2.11 Million - $2.93 Million	27,865 Added 53.29%	80,157 $10.2 Million
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $527,763 - $852,660	8,190 Added 18.57%	52,292 $8.23 Million
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $7.81 Million - $12.3 Million	-132,071 Reduced 74.97%	44,102 $4.38 Million
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $79,174 - $104,683	-891 Reduced 0.5%	176,173 $25.7 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $438,515 - $561,523	4,401 Added 2.55%	177,064 $27.8 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $18.3 Million - $26.1 Million	172,663 New	172,663 $29.5 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Capital Bank & Trust CO, based on Form 13F filings with the SEC.

Stay updated on Capital Bank & Trust CO with notifications on news.